"Eleven clinical trials that will shape medicine in 2026" - BriaCell Phase 3 Trial Featured in Nature Medicine

Executive Summary

• BriaCell’s Phase 3 BRIA‑ABC trial in metastatic breast cancer was highlighted by Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.”
• The company expects to report top‑line data from the trial as early as the first half of 2026.
• Interim analysis will be triggered after 144 patient deaths, with overall survival as the primary endpoint; positive results could support full FDA approval of Bria‑IMT.

Key Details

• Media Feature: The trial was independently featured in Nature Medicine Year In Review (Vol 31, p.3943‑3947).
• Trial Design: Phase 3 BRIA‑ABC evaluates Bria‑IMT plus an immune checkpoint inhibitor versus physician’s choice therapy in advanced metastatic breast cancer.
• Enrollment Status: >230 patients screened; >160 patients enrolled to date.
• Interim Analysis Trigger: 144 patient events (deaths) will initiate interim analysis of overall survival (OS).
• Regulatory Status: Bria‑IMT combination regimen has received FDA Fast Track designation.
• Data Timeline: Top‑line results anticipated in H1 2026; interim data to be analyzed once the event threshold is met.
• ClinicalTrials.gov Identifier: NCT06072612 (for additional trial information).

Notable Quotes

“The BRIA‑ABC trial is an exciting study focused on people living with metastatic breast cancer… it welcomes individuals with all breast cancer subtypes, including patients with brain metastases and extensive prior treatments.” – Dr. Sara A. Hurvitz, MD, FACP, Fred Hutchinson Cancer Center.